Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company is expected to achieve a significant reduction in losses, with a projected net profit attributable to shareholders of -300 million to -240 million yuan for 2025, compared to -679.88 million yuan in 2024 [1] - The company is benefiting from the high demand for lithium iron phosphate (LFP) due to the recovery of profitability in the industry and increased demand for energy storage [1] - The company has a saturated order book and a production capacity utilization rate exceeding 95% [2] Financial Summary - The company forecasts a revenue of 3.645 billion yuan for 2025, a year-on-year increase of 141.2%, and expects to reach 5.825 billion yuan in 2026 and 9.745 billion yuan in 2027 [5] - The projected net profit for 2026 is 68 million yuan, and for 2027, it is 304 million yuan, indicating a strong recovery trajectory [5] - The gross margin is expected to improve from -11.1% in 2024 to 8.3% in 2026 and 8.7% in 2027 [8] Industry Insights - The lithium battery shipment in China is projected to reach 1875 GWh in 2025, a 53% year-on-year increase, with LFP battery shipments expected to grow by 130% [3] - The demand for LFP materials is also expected to rise, with shipments projected at 390 million tons in 2025, reflecting a 58% increase [3]

Investment Rating - The report does not explicitly state an investment rating for the company. Core Insights - Haisheng Medical is recognized as a national-level specialized and innovative "little giant" in the field of anesthesia and monitoring medical devices, with a comprehensive product offering and strong market presence in China [3][18]. - The company has a solid growth trajectory, with revenue expected to reach 304 million yuan in 2024, a slight decrease of 0.70% year-on-year, but showing positive growth in the first three quarters of 2025 with a revenue increase of 19.89% [3][12]. - The company has a robust technology matrix with 63 patents, including 13 invention patents, and has undertaken numerous significant technology projects at various governmental levels [3][18]. Company Overview - Haisheng Medical specializes in anesthesia and monitoring medical devices, serving major clinical departments such as anesthesia, ICU, and emergency [3][15]. - The company has established a strong brand and marketing network, with products used in over 600 top-tier hospitals, including prestigious institutions like Peking Union Medical College Hospital [5][12]. - The revenue composition for 2024 indicates that anesthesia products account for 52.60%, monitoring products for 36.59%, and surgical and nursing products for 10.47% [30][33]. Financial Performance - In 2024, the company is projected to achieve a gross margin of 52.09% and a net margin of 23.35% [12][30]. - The net profit attributable to the parent company for 2024 is expected to be approximately 70.92 million yuan, reflecting a year-on-year decline of 9.12% [12][30]. - The company’s R&D expenses for 2024 are estimated at 16.16 million yuan, representing 5.32% of revenue, with a year-on-year growth of 21.67% in the first three quarters of 2025 [5][12]. Industry Analysis - The medical device market in China is rapidly growing, with the market size expected to increase from 440.3 billion yuan in 2017 to 1.1544 trillion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 14.76% [4][18]. - The low-value medical consumables market is projected to reach 185.2 billion yuan in 2024, with a year-on-year growth of 19.49% [4][30]. - The global medical device industry is also on an upward trend, with the market size expected to grow from 479.36 billion USD in 2023 to 637.96 billion USD by 2028 [4][18]. Competitive Position - Haisheng Medical's performance in terms of revenue growth is superior compared to its peers, with the company leading in revenue CAGR among comparable companies from 2022 to 2024 [12][14]. - The company has established a strong competitive edge through its proprietary technologies and extensive patent portfolio, which includes critical innovations in blood pressure sensors and bioelectrical signal acquisition [5][12].

有色金属/工业金属 江西铜业（600362.SH） 铜冶炼龙头再起航，资源并购助成长 投资评级：买入（首次） | 日期 | 2026/2/2 | | --- | --- | | 当前股价(元) | 57.08 | | 一年最高最低(元) | 70.70/19.01 | | 总市值(亿元) | 1,976.53 | | 流通市值(亿元) | 1,184.55 | | 总股本(亿股) | 34.63 | | 流通股本(亿股) | 20.75 | | 近 3 个月换手率(%) | 196.62 | 股价走势图 -80% 0% 80% 160% 240% 320% 2025-02 2025-06 2025-10 江西铜业 沪深300 数据来源：聚源 孙二春（分析师） 冯伟珉（联系人） sunerchun@kysec.cn 2026 年 02 月 03 日 fengweimin@kysec.cn 证书编号：S0790124070040 并购投资项目持续落地，铜业龙头再起航 江西铜业是国内领先的铜冶炼生产商，在铜以及相关有色金属领域建立了集勘 探、采矿、选矿、冶炼、加工的一体化产业链。目前公司主要资产包括国内规模 领先的 ...

北交所新股申购报告 海圣医疗（920166.BJ）：麻醉监护医疗器械小巨人，麻醉监护精准化矩阵驱动成长 北交所研究团队 ——北交所新股申购报告 | 诸海滨（分析师） | 车欣航（分析师） | | --- | --- | | zhuhaibin@kysec.cn | chexinhang@kysec.cn | | 证书编号：S0790522080007 | 证书编号：S0790525050001 | 海圣医疗：麻醉、监护类医疗器械细分领域国家级专精特新"小巨人" 海圣医疗是面向全球的麻醉、监护类医疗器械综合产品提供商，为国内该细分领 域头部企业，获评国家级专精特新"小巨人"、浙江省隐形冠军企业等。公司产 品广泛应用于麻醉科、ICU、急诊科等临床科室。技术研发上，截至 2025 年 6 月 30 日，公司已先后承担国家、省、市级重大科技项目十余项，已累计获国家 授权专利 63 项，其中发明专利 13 项。经营层面，2024 年公司营收 3.04 亿元， 同比微降 0.70%，归母净利润 7091.75 万元；2025 年前三季度营收、归母净利润 同比分别增长 19.89%、26.70%，增长态势向好。2024 年 ...

行 业 研 究 银行 2026 年 02 月 03 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 2025-02 2025-06 2025-10 银行 沪深300 相关研究报告 《2026 年初银行存贷形势更新与展望 —行业深度报告》-2026.1.26 《规模高增&收益承压，"存款+基金" 成配置主线—理财登 2025 年报解读》 《企业信贷超季节性增长，信贷投放 前置趋势或延续 —行业点评报告》 -2026.1.16 2026 年净息差展望：筑底企稳 ——行业深度报告 刘呈祥（分析师） 朱晓云（分析师） liuchengxiang@kysec.cn 证书编号：S0790523060002 zhuxiaoyun@kysec.cn 证书编号：S0790524070010 理论估算 1.4%净息差支撑 6%左右的 RWA 增速 据我们测算，银行若保持 RWA 6%-7%的增速，理论净息差大约在 1.44%-1.57% 是底线水平，2025Q3 商业银行净息差为 1.42%，意味着银行资产扩张面临内生 资本补充的现实硬约束，"稳息差"仍然是 2026 年银行核心经 ...

- The report does not contain any quantitative models or factors for analysis[1][2][3]

税收收入同比转负，投资于人重要性凸显 固定收益研究团队 陈曦（分析师） 王帅中（联系人） chenxi2@kysec.cn 证书编号：S0790521100002 wangshuaizhong@kysec.cn 证书编号：S0790125070016 事件：财政部公布 2025 年 12 月财政数据，1-12 月全国一般公共预算收入同比下 降 1.7%（前值为+0.8%，下同），支出同比增长 1.0%（+1.4%）；1-12 月全国政府 性基金预算收入同比下降 7.0%（-4.9%），支出同比增长 11.3%（+13.7%）。 2026 年 02 月 02 日 ——2025 年 12 月财政数据点评 12 月财政数据的关注点 税收收入同比转负，非税收入降幅扩大。12 月税收收入同比下降 11.5%（+2.8%）， 同比转负，结束连续 8 个月的正增长，12 月企业所得税回落或为当月税收收入 增幅放缓的主要原因。12 月证券交易印花税同比下降 4.8%，增幅在 12 月权益市 场震荡调整与 2024 年同期基数回升影响下转负。非税收入降幅的扩大或因 2024 年一次性安排中央单位上缴专项收益抬高基数。 在投资于 ...

2026 年 02 月 02 日 券商金股解析月报（2026 年 02 月） 金融工程研究团队 苏俊豪（分析师） 证书编号：S0790522020001 胡亮勇（分析师） 证书编号：S0790522030001 王志豪（分析师） 证书编号：S0790522070003 魏建榕（首席分析师） 证书编号：S0790519120001 傅开波（分析师） 证书编号：S0790520090003 高 鹏（分析师） 证书编号：S0790520090002 盛少成（分析师） 证书编号：S0790523060003 蒋 韬（分析师） 证书编号：S0790525070001 相关研究报告 《开源量化评论（23）-"金股+"组 合的量化方案》-2021.4.26 《开源量化评论（32）-券商金股的内 部收益结构》-2021.8.29 魏建榕（分析师） 高鹏（分析师） weijianrong@kysec.cn 证书编号：S0790519120001 gaopeng@kysec.cn 证书编号：S0790520090002 2 月份券商金股特征解析 2 月份紫金矿业、中际旭创、海光信息、万华化学、贵州茅台、福斯特、山东黄 金等金股推 ...

2026 年 02 月 02 日 券商金股解析月报（2026 年 02 月） 金融工程研究团队 魏建榕（首席分析师） 证书编号：S0790519120001 傅开波（分析师） 证书编号：S0790520090003 高 鹏（分析师） 证书编号：S0790520090002 苏俊豪（分析师） 证书编号：S0790522020001 胡亮勇（分析师） 证书编号：S0790522030001 王志豪（分析师） 证书编号：S0790522070003 盛少成（分析师） 证书编号：S0790523060003 蒋 韬（分析师） 证书编号：S0790525070001 相关研究报告 《开源量化评论（23）-"金股+"组 合的量化方案》-2021.4.26 《开源量化评论（32）-券商金股的内 部收益结构》-2021.8.29 魏建榕（分析师） 高鹏（分析师） weijianrong@kysec.cn 证书编号：S0790519120001 gaopeng@kysec.cn 证书编号：S0790520090002 2 月份券商金股特征解析 2 月份紫金矿业、中际旭创、海光信息、万华化学、贵州茅台、福斯特、山东黄 金等金股推 ...

Index Adjustment - The North Exchange 50 Index will undergo its first adjustment of 2026 on March 16, with three companies expected to be added: Tiangong Co., Ltd., Guangxin Technology, and Jikang Technology[2][14] - The adjustment will remove companies that rank low based on average daily market capitalization, with no substantial impact on the operations of the companies being removed[2][18] Index Fund Growth - The scale of North Exchange 50 index funds has seen significant growth from 2.94 billion CNY in 2022 to 14.165 billion CNY by January 31, 2026[2][18] - The number of products tracking the North Exchange 50 index increased from 16 in 2022 to 79 by the end of January 2026[2][18] Market Performance - The North Exchange 50 Index closed at 1,531.55 points, down 3.59% from the previous week, with a price-to-earnings ratio (PETTM) of 64.12X[2][32] - The overall PE ratio for North Exchange A-shares decreased to 47.58X, while the ChiNext and STAR Market also saw declines in their PE ratios[2][23][32] Liquidity and Trading Activity - The average daily trading volume for North Exchange A-shares was 29.948 billion CNY, reflecting an increase of 11.62% week-over-week[2][26] - The average turnover rate for North Exchange A-shares was 5.88%, up by 0.44 percentage points[2][26] Valuation Trends - As of January 31, 2026, 44.86% of North Exchange companies had a PETTM exceeding 45X, indicating a high valuation environment[2][37] - The valuation gap between North Exchange and other markets is widening, suggesting a relative valuation advantage for North Exchange stocks[2][47]